Encouragingly, we noted that a correlated enrichment of MBD3 and 5hmC (the preferable binding site of MBD3 in brain tissues [15]) within glioma cells indicated a better PFS and OS in patients, which confers a promising basis for future large-scale clinical studies. This evidence concerns the gene MBD3 and central nervous system cancer.